LQDA Stock Analysis: Liquidia Technologies | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 4.285m USD | 12M Return: 88.6% | US53635D2027 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 143M
Qual. Beats: 0
Rev. Trend: 82.3%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.3 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Liquidia Corporation is a U.S. biopharmaceutical company focused on treatments for rare cardiopulmonary diseases, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its portfolio includes treprostinil products and candidates: Remodulin injection, YUTREPIA inhaled dry powder, and L606, which is in Phase III trials.
The company also uses its PRINT technology to engineer drug particles with controlled size, shape, and composition. Like other pharmaceutical businesses, Liquidia combines product commercialization with clinical development, where investigational medicines must undergo trials and regulatory review.
- YUTREPIA launch targets share of the inhaled treprostinil market
- United Therapeutics patent litigation threatens commercialization timing
- L606 Phase III progress could expand the long-term growth pipeline
| Net Income: 138.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 59.76 > 1.0 |
| NWC/Revenue: 55.09% < 20% (prev 606.4%; Δ -551.3% < -1%) |
| CFO/TA 0.15 > 3% & CFO 79.0m > Net Income 138.6m |
| Net Debt (-148.4m) to EBITDA (177.8m): -0.83 < 3 |
| Current Ratio: 2.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (101.4m) vs 12m ago 18.47% < -2% |
| Gross Margin: 92.48% > 18% (prev 70.36%; Δ 22.12% > 0.5%) |
| Asset Turnover: 115.7% > 50% (prev 7.51%; Δ 108.2% > 0%) |
| Interest Coverage Ratio: 6.61 > 6 (EBIT TTM 176.1m / Interest Expense TTM 26.6m) |
| A: 0.48 (Total Current Assets 437.7m - Total Current Liabilities 189.3m) / Total Assets 521.9m |
| B: -0.96 (Retained Earnings -498.7m / Total Assets 521.9m) |
| C: 0.45 (EBIT TTM 176.1m / Avg Total Assets 389.7m) |
| D: 0.60 (Book Value of Equity 195.1m / Total Liabilities 326.8m) |
| Altman-Z'' = 3.67 = AA |
| DSRI: 0.47 (Receivables 108.6m/9.97m, Revenue 450.9m/19.3m) |
| GMI: 0.76 (GM 70.36% / 92.48%) |
| AQI: 0.47 (AQ_t 0.09 / AQ_t-1 0.19) |
| SGI: 23.34 (Revenue 450.9m / 19.3m) |
| TATA: 0.11 (NI 138.6m - CFO 79.0m) / TA 521.9m) |
| Beneish M = 12.03 (Cap -4..+1) = D |
As of November 11, 2026, the stock is trading at USD 51.40 with a total of 2,847,088 shares traded. Over the past week, the price has changed by +21.80%, over one month by +85.76%, over three months by -43.54% and over the past year by +88.55%.
Current recommended Stop Loss: 46.90 (which is 8.8% or 1.2 ATR below the current price).
Liquidia Technologies has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy LQDA.
- StrongBuy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 54.4 | 5.8% |
P/E Trailing = 34.4389
P/E Forward = 11.0865
P/S = 9.5026
P/B = 20.3502
Revenue TTM = 450.9m USD
EBIT TTM = 176.1m USD
EBITDA TTM = 177.8m USD
Long Term Debt = 122.2m USD (from longTermDebt, last quarter)
Short Term Debt = 899k USD (from shortTermDebt, last quarter)
Debt = 135.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.79m
Net Debt = -148.4m USD (calculated: Debt 135.7m - CCE 284.2m)
Enterprise Value = 4.14b USD (4.28b + Debt 135.7m - CCE 284.2m)
Interest Coverage Ratio = 6.61 (Ebit TTM 176.1m / Interest Expense TTM 26.6m)
EV/FCF = 68.36x (Enterprise Value 4.14b / FCF TTM 60.5m)
FCF Yield = 1.46% (FCF TTM 60.5m / Enterprise Value 4.14b)
FCF Margin = 13.42% (FCF TTM 60.5m / Revenue TTM 450.9m)
Net Margin = 30.74% (Net Income TTM 138.6m / Revenue TTM 450.9m)
Gross Margin = 92.48% ((Revenue TTM 450.9m - Cost of Revenue TTM 33.9m) / Revenue TTM)
Gross Margin QoQ = 93.27% (prev 90.86%)
Tobins Q-Ratio = 7.93 (Enterprise Value 4.14b / Total Assets 521.9m)
Interest Expense / Debt = 19.62% (Interest Expense 26.6m / Debt 135.7m)
Taxrate = 8.54% (6.97m / 81.7m)
NOPAT = 161.1m (EBIT 176.1m * (1 - 8.54%))
Current Ratio = 2.31 (Total Current Assets 437.7m / Total Current Liabilities 189.3m)
Debt / Equity = 0.70 (Debt 135.7m / totalStockholderEquity, last quarter 195.1m)
Debt / EBITDA = -0.83 (Net Debt -148.4m / EBITDA 177.8m)
Debt / FCF = -2.45 (Net Debt -148.4m / FCF TTM 60.5m)
Total Stockholder Equity = 92.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 35.57% (Net Income 138.6m / Total Assets 521.9m)
RoE = 149.6% (Net Income TTM 138.6m / Total Stockholder Equity 92.6m)
RoCE = 82.01% (EBIT 176.1m / Capital Employed (Equity 92.6m + L.T.Debt 122.2m))
RoIC = 51.80% (NOPAT 161.1m / Invested Capital 311.0m)
WACC = 8.01% (E(4.28b)/V(4.42b) * Re(7.70%) + D(135.7m)/V(4.42b) * Rd(19.62%) * (1-Tc(0.09)))
Discount Rate = 7.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.16 | Cagr: 14.08%
[DCF] Terminal Value 75.44% ; FCFF base≈60.5m ; Y1≈60.8m ; Y5≈64.4m
[DCF] Fair Price = 12.84 (EV 1.00b - Net Debt -148.4m = Equity 1.15b / Shares 89.5m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.53 | # QB: 0
Revenue Correlation: 82.27 | Revenue CAGR: 227.7% | SUE: -2.61 | # QB: -1
EPS current Year (2026-12-31): EPS=2.03 | Chg30d=-41.03% | Revisions=-57% | GrowthEPS=+353.4% | GrowthRev=+352.9%
EPS next Year (2027-12-31): EPS=2.19 | Chg30d=-65.06% | Revisions=-57% | GrowthEPS=+7.9% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: -73% (up=0, down=8)